

- EHR Contract signed with Region Stockholm and Gotland
- Live with Cambio COSMIC in all Sussa regions
- Revenue growth of 34% in the Quarter – and 16% for full year


**Q4, October - December 2025**

- Revenue amounted to 458.4 (342.3) MSEK in the fourth quarter, representing growth of 33.9%
- Adjusted EBITDA amounted to 163.0 (69.0) MSEK, representing growth of 136.2%
- Income before tax amounted to 62.6 (-15.7) MSEK
- Net income per share amounts to 0.35 SEK (-0.17)

**January – December 2025**

- Revenue January – December amounted to 1,379.3 (1,193.9) MSEK
- Adjusted EBITDA amounted to 256.3 (204.5) MSEK
- Income before tax amounted to -100.0 (-103.7) MSEK
- Net income per share amounts to -0.57 SEK (-0.70)

**Revenue, MSEK**



**Key figures**

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Revenue	458.4	342.3	1,379.3	1,193.9
Adjusted EBITDA	163.0	69.0	256.3	204.5
<i>Adjusted EBITDA-margin</i>	35.6%	20.2%	18.6%	17.1%
Financial net	-23.3	-26.0	-72.7	-85.8
Income before tax	62.6	-15.7	-100.0	-103.7
Net income	58.6	-28.6	-95.0	-115.3

Sanolium AB is the parent company in the Cambio Group, since February 20, 2019. The largest operating subsidiary in that group is Cambio Healthcare Systems which was founded in 1993 to deliver comprehensive IT solutions for healthcare organizations. Today, Cambio is an e-health company providing smart, reliable and user-friendly solutions to improve healthcare and patient safety with a market leading position in the Nordics including more than 100 000 users. We are committed to improve healthcare and patient safety.

## CEO's Comments

Cambio continued to execute on its strategic priorities during the quarter, delivering strong financial performance alongside important commercial and operational milestones. Revenue in the fourth quarter increased by 34% year-on-year to 458 MSEK, while Adjusted EBITDA more than doubled, increasing by 136% to 163 MSEK. For the full year, revenue grew by 16% to 1,379 MSEK, with Adjusted EBITDA increasing to 256 MSEK, reflecting both higher volumes and improved operational leverage.

A key strategic highlight during the period was the signing of the agreement with Region Stockholm and Region Gotland (RSRG) for the delivery of Cambio COSMIC as the core Electronic Health Record solution. This agreement represents a major step forward for Cambio and further strengthens our position as a trusted partner for large-scale, mission-critical healthcare IT programmes. It also confirms the long-term confidence in our platform, delivery capability and roadmap.



Operational execution progressed well during the quarter. We successfully went live with Cambio COSMIC in Region Blekinge and Region Dalarna. With these go-lives completed, all Sussa regions are now live on COSMIC. Together with the earlier go-live in Åland, this means that Cambio has gone live with ten regions within a period of fifteen months — a significant achievement that validates the scalability of our platform and delivery model.

As we move into the next phase, our focus is increasingly on preparing for the implementation of the RSRG programme, while stabilising operations and driving performance across the Sussa regions as they transition into steady-state operations. In parallel, we continue to invest in and deliver new functionality across all customer groups to support evolving clinical and operational needs.

Looking ahead, Cambio enters the coming quarters with confidence. Strong financial momentum, successful large-scale deliveries and the signing of strategically important contracts reinforce our long-term direction. We remain committed to working closely with our customers to deliver secure, reliable and future-proof solutions that enable better care outcomes and more efficient healthcare systems.

**Rami Avidan, CEO**

## Fourth quarter

Revenue in the fourth quarter amounted to 458.4 (342.3) MSEK, representing an increase of 33.9%. Revenue growth was primarily driven by the initiation of implementation activities within the RSRG programme. In addition, recurring revenue following the go-live in Åland, together with increased sales of third-party products, contributed positively.

During the quarter, the company entered into a new customer agreement which, following an accounting assessment, was determined to meet the criteria for contract combination under IFRS 15.17. Accordingly, the agreement is accounted for together with an existing performance obligation as a single combined contract, as the promised goods and services were assessed to be commercially interrelated and attributable to a common delivery model.


This assessment resulted in revenue related to previously partially satisfied performance obligations being recognised in the quarter in accordance with IFRS 15 principles for combined performance obligations. The effect is a significant increase in reported revenue in the fourth quarter, reflecting the actual transfer of value to the customer during the period.

The company continues to monitor delivery progress and will, in line with applicable IFRS requirements, continuously assess revenue recognition, progress towards completion, and any adjustments to the remaining performance obligations.

Adjusted EBITDA in the fourth quarter amounted to 163.0 (69.0) MSEK, resulting in an adjusted EBITDA margin of 35.6% (20.2%). The improvement in profitability was mainly attributable to higher sales volumes and favourable operational leverage, generating strong margin drop-through during the quarter.

Personnel costs amounted to 217.7 (196.8) MSEK, representing an increase of 10.7%. The number of full-time equivalents (FTEs) was 1,049 at the end of the fourth quarter, an increase of 10.6% compared to the corresponding period last year. The increase in personnel costs is primarily related to the RSRG programme and, to a lesser extent, ongoing Sussa deliveries.

Depreciation and amortisation amounted to 67.1 MSEK, of which 25.2 MSEK relates to amortisation of intangible assets from M&A activities, 25.0 MSEK refers to amortisation of capitalised R&D, and 12.5 MSEK relates to financial leases. The remaining depreciation of tangible assets amounted to 4.4 MSEK. Non-recurring items amounted to 10.0 MSEK and are specified in the table on page 7.



## Year-to-date

Revenue year-to-date amounted to 1,379.3 (1,193.9) MSEK, representing an increase of 15.5%. Revenue growth was driven by the initiation of the RSRG implementation programme, continued growth in recurring maintenance and support revenue, and revenues related to the implementation and go-live of Cambio COSMIC in the Sussa regions and Åland.

Adjusted EBITDA year-to-date amounted to 256.3 (204.5) MSEK, resulting in an adjusted EBITDA margin of 18.6% (17.1%). The improvement in margin reflects revenue growth combined with increasing operational efficiency as earlier investments in the organisation scale.

Personnel costs amounted to 806.4 (727.3) MSEK, representing an increase of 10.9%.

Depreciation and amortisation amounted to 259.7 MSEK, of which 97.6 MSEK relates to amortisation of intangible assets from M&A activities, 109.5 MSEK to amortisation of capitalised R&D, and 38.0 MSEK to financial leases. The remaining depreciation of tangible assets amounted to 14.6 MSEK.

## Liquid funds and cash conversion

At the end of the fourth quarter, Cambio's cash amounted to 524.5 MSEK. In addition, Cambio had access to an undrawn credit facility of 200.0 MSEK.

Cambio's cash conversion profile is primarily influenced by maintenance fees, which are largely invoiced for the year or for the quarter in advance. As a significant portion of invoices is issued in the fourth quarter, quarterly cash conversion figures are not directly comparable.

In March 2024, Sanolium AB issued a senior secured bond with a total nominal amount of 1,000 MSEK within a framework of 1,500 MSEK, and the previous bond of 800 MSEK was amortised. The bond matures in March 2029 and carries a floating interest rate of STIBOR 3m plus 4.00%

## Leverage

At the end of the fourth quarter, leverage amounted to 4.3x LTM Q4-25 EBITDA. Leverage is calculated in accordance with the methodology set out in the table on the right and is consistent with the definitions agreed under the existing bond terms.

## Balance sheet

Fixed assets represented 64.9% of total assets, of which 93.1% comprised intangible assets subject to impairment testing. Management considers these assets to provide a solid foundation to support future profitability and growth.

External interest-bearing debt amounted to 1,114.4 MSEK, of which 984.8 MSEK relates to the utilised bond facility and 129.6 MSEK relates to financial lease liabilities recognised under IFRS 16.

The senior secured bond bears a floating interest rate of STIBOR 3m plus 4.0%. To mitigate interest rate risk, Sanolium AB has entered into an interest rate cap transaction. Under this arrangement, the floating interest rate on a notional amount of 500 MSEK is capped at 3.5%. The derivative matures in March 2029 and is measured at fair value using a valuation technique based on observable market inputs

## Risks

The Group's operations are exposed to various financial risks, including market risks (currency risk and interest rate risk), credit risk and liquidity risk. The Group seeks to minimise the potential adverse impact of these risks on its financial performance.


The Group's exposure to currency risk primarily arises from transactions between Cambio group entities conducted in foreign currencies. The Group does not currently use derivative instruments to hedge currency risk.

Following the issuance in March 2024 of a senior secured floating-rate bond with a nominal amount of 1,000 MSEK, the Group is exposed to interest rate movements. To mitigate this exposure, Sanolium AB has entered into an interest rate cap transaction with DNB Bank ASA. Further details are provided in the Balance sheet section on page 4. For a more comprehensive description of the risks facing the Group, reference is made to the Annual Report 2024.

### Leverage, MSEK

Liability	1,114.4
Net debt (Liability-surplus cash)	1,114.4
Applicable LTM EBITDA	256.7
Leverage (Net debt/EBITDA)	4.3

### Balance sheet



Fixed Assets	65%
Short term assets	20%
Liquid funds	15%
Equity	24%
Utilized bond facility	29%
Other liabilities	48%

## Other events

The administrative court rejected the Swedish Competition Authority's lawsuit against the nine Sussa regions concerning alleged unlawful direct procurement and therefore ruled that no fines were to be imposed. On 13 November, the Competition Authority appealed the decision to the Administrative Court of Appeal. We do not expect the ultimate conclusion, which is that the Sussa regions did not violate the public procurement legislation, to be altered.

*Stockholm, 27 February 2026*

**Rami Avidan**

CEO

## Consolidated income statement

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Net sales	419.5	309.1	1,236.5	1,068.5
Other revenue	38.9	33.2	142.8	125.4
Capitalized R&D	52.7	37.2	164.1	158.3
<b>Total</b>	<b>511.1</b>	<b>379.5</b>	<b>1,543.4</b>	<b>1,352.2</b>
Other external expenses	-140.4	-118.6	-504.6	-452.2
Personnel cost	-217.7	-196.8	-806.4	-727.3
Depreciation	-67.1	-53.8	-259.7	-190.6
<b>Operation income</b>	<b>85.9</b>	<b>10.3</b>	<b>-27.3</b>	<b>-17.9</b>
Finance income	33.0	31.4	42.9	52.0
Finance cost	-56.3	-57.4	-115.6	-137.8
Financial net	-23.3	-26.0	-72.7	-85.8
<b>Income before tax</b>	<b>62.6</b>	<b>-15.7</b>	<b>-100.0</b>	<b>-103.7</b>
Tax	-4.0	-12.9	5.0	-11.6
<b>Net income</b>	<b>58.6</b>	<b>-28.6</b>	<b>-95.0</b>	<b>-115.3</b>

## Consolidated statement of comprehensive income

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Net income</b>	<b>58.6</b>	<b>-28.6</b>	<b>-95.0</b>	<b>-115.3</b>
<b>Other comprehensive income</b>				
Exchange differences in translating foreign operations	-2.5	-4.3	-9.8	4.9
Total comprehensive income for the period	<b>56.1</b>	<b>-32.9</b>	<b>-104.8</b>	<b>-110.4</b>
<b>Total comprehensive income attributable to:</b>				
<i>Equity holders of the parent company</i>	56.1	-32.9	-104.8	-110.4
Non controlling interest	N/A	N/A	N/A	N/A

## Specification of revenue divided into categories

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
License revenue	86.4	82.6	237.6	228.0
Maintenance revenue	162.6	158.5	650.1	628.4
Professional Services	170.5	68.0	348.8	212.2
Other revenue	38.9	33.2	142.8	125.4
<b>Total revenue</b>	<b>458.4</b>	<b>342.3</b>	<b>1,379.3</b>	<b>1,194.0</b>

## Reconciliation of operating income to Adjusted EBITDA

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Operating income	85.9	10.3	-27.3	-17.9
Depreciation	67.1	53.8	259.7	190.6
Non recurring items	10.0	4.9	23.9	31.8
<b>Adjusted EBITDA</b>	<b>163.0</b>	<b>69.0</b>	<b>256.3</b>	<b>204.5</b>

## Non recurring items relating to:

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Non operational consultancy fee	-2.3	-3.6	-7.3	-20.5
Management fees	-1.0	-1.0	-2.0	-2.0
Discontinued operation	-2.0		-2.0	
Organizational adjustments	-0.5		-7.5	-8.5
Other	-4.2	-0.2	-5.1	-0.7
<b>Total non recurring items</b>	<b>-10.0</b>	<b>-4.8</b>	<b>-23.9</b>	<b>-31.7</b>



Cambio MittVaccin enables the inhabitant to find and book the vaccination they need as well as keep track on prior vaccinations.

## Consolidated balance sheet

<b>MSEK</b>	<b>2025-12-31</b>	<b>2024-12-31</b>
<i>Fixed Assets</i>		
Intangible assets	2,067.9	2,073.9
Tangible assets	24.5	23.4
Right-of-use assets	126.4	72.0
Financial assets	1.3	3.9
<b>Total Fixed Assets</b>	<b>2,220.1</b>	<b>2,173.2</b>
<i>Current Assets</i>		
Inventory	0.3	0.3
Contract assets	307.8	215.0
Accounts receivables	259.9	315.4
Other receivables	11.6	10.0
Tax receivables	22.0	10.8
Prepaid expenses and accrued income	73.7	54.9
Cash and cash equivalents	524.5	591.4
<b>Total Current Assets</b>	<b>1,199.8</b>	<b>1,197.8</b>
<b>Total Assets</b>	<b>3,419.9</b>	<b>3,371.0</b>
<i>Equity</i>		
Share capital	1.7	1.7
Other equity including net income for the financial year	805.5	896.7
<b>Total Equity</b>	<b>807.2</b>	<b>898.4</b>
<i>Non-current liabilities</i>		
Pension obligations	23.4	6.6
Bond loan	984.8	980.0
Lease liabilities	89.3	50.2
Deferred tax liabilities	324.8	329.6
<b>Total non current liabilities</b>	<b>1,422.3</b>	<b>1,366.4</b>
<i>Other liabilities</i>		
Advance payments	0.6	1.3
Accounts payable	66.1	39.5
Lease liabilities	40.3	24.8
Other liabilities	201.2	197.0
Accrued expenses	127.3	113.6
Deferred income	754.9	730.0
<b>Total Other Liabilities</b>	<b>1,190.4</b>	<b>1,106.2</b>
<b>Total Equity and Liabilities</b>	<b>3,419.9</b>	<b>3,371.0</b>

## Changes in group equity

<b>MSEK</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Opening balance	898.4	1,008.8
Total comprehensive income for the period	-104.8	-110.4
<b>Total change excluding owner transactions</b>	<b>793.6</b>	<b>898.4</b>
Shareholder contributions	13.6	
<b>Equity at the end of the period</b>	<b>807.2</b>	<b>898.4</b>
Attributable to equity holders of the parent company	807.2	898.4
Non-controlling interest	N/A	N/A

## Consolidated cashflow statement

<b>MSEK</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Income after financial items	-100.0	-103.7
Adjusted for non-cash items	264.4	218.2
Taxes paid	-11.3	-3.8
Changes in working capital	10.9	59.7
<b>Cash flow from operating activities</b>	<b>164.0</b>	<b>170.4</b>
Investments in intangibles/tangibles	-182.6	-167.8
Investments in subsidiaries	-5.8	
<b>Cashflow from investing activities</b>	<b>-188.4</b>	<b>-167.8</b>
Bond issue less financing fees		977.0
Repayment of bond loans		-800.0
Repayment of bank loans	-4.0	
Acquisition of derivative and credit guarantee		-4.0
Lease payments	-38.5	-28.4
	<b>-42.5</b>	<b>144.6</b>
<b>Changes in cash and cash equivalents</b>	<b>-66.9</b>	<b>147.2</b>
<b>Opening cash and cash equivalents balance</b>	<b>591.4</b>	<b>444.2</b>
<b>Cash and cash equivalents by end of the period</b>	<b>524.5</b>	<b>591.4</b>

## Segment reporting

The group recognizes only a single segment in accordance with the definition of operating segment in IFRS 8. The starting point for identifying operating segments on which separate information can be provided are the internal reports to and monitoring by the group management. The group management monitors operating income for the entire business as one operating segment.

## Timing of revenue

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
<b>Timing of revenue recognition</b>				
At a point in time	295.8	183.8	729.2	565.6
Over time	162.6	158.5	650.1	628.3
	<b>458.4</b>	<b>342.3</b>	<b>1,379.3</b>	<b>1,193.9</b>

At a point in time is defined as revenue correlated to working hours while "over time" is not.

## Intangible assets

<b>MSEK</b>	<b>Capitalized development expenditure</b>	<b>Customer contracts</b>	<b>Trademarks</b>	<b>Technology</b>	<b>Goodwill</b>	<b>Total</b>
At 31 Dec 2024	547.4	375.5	89.0	599.2	462.8	2,073.9
Acquisitions for the period	164.1	5.8	1.6	6.6	24.8	202.9
Depreciation for the period	-109.5	-30.6	-0.2	-66.9		-207.2
Exchange rate changes	-1.7					-1.7
<b>At 31 Dec 2025</b>	<b>600.3</b>	<b>350.7</b>	<b>90.4</b>	<b>538.9</b>	<b>487.6</b>	<b>2,067.9</b>

## Fair value measurement of financial instruments

To provide an indication about the reliability of the inputs used in determining fair value, the group classifies its financial instruments into three levels prescribed under the accounting standards. No transfers between levels has been made during the period.

As per December 31 2025, the group had the following financial assets and liabilities at fair value.

<b>At 31 Dec 2025</b>	<b>Level 1</b> Value of financial instruments traded in active markets	<b>Level 2</b> Value based on observable market data	<b>Level 3</b> Value based on other observable data
<b>Financial assets</b>			
Interest rate cap	-	1.3	-
<b>Financial liabilities</b>	-	-	-
<b>At 31 Dec 2024</b>			
<b>Financial assets</b>			
Interest rate cap	-	4.0	-
<b>Financial liabilities</b>	-	-	-

The calculation of fair value of the interest cap is based on level 2 input using observable market data through profit and loss.

The group's other financial assets and liabilities are valued at accrued acquisition cost and do not materially differ from fair value.

## Applicable Accounting Rules

Sanolium AB complies with IFRS standards and interpretations (IFRIC) as adopted by the EU. This Interim Report has been prepared in accordance with IAS 34 Interim Financial Reporting. The Parent Company's financial statements have been prepared in accordance with RFR 2. The accounting policies applied are consistent with those presented in the Annual Report for 2024, except for the adoption of standard amendments effective as of January 1, 2025. The amendments are not expected to have any material impact on the financial statements.

Detailed information about the Group's accounting and valuation principles can be found in the Annual Report for 2024 which is available on [www.cambio.se](http://www.cambio.se).

This interim report refers to certain key performance indicators which Cambio and others use when evaluating the performance of Cambio. These are referred to as alternative performance measures (APMs) and are not defined under IFRS. The figures give management and investors important information and enable both to analyse Cambio's business and trends. The APMs are not meant to replace but to complement the performance measures defined under IFRS.

## Significant estimates and assessments

The Group carries out estimates and assumptions about the future. The estimates for accounting purposes resulting from these will, by definition, rarely correspond to the real results. The main features of the estimates and assumptions that mean a significant risk of substantial adjustments to the carrying amounts for assets and liabilities during the next financial year are considered below.

### Goodwill and trademarks

Each year, the Group examines whether there is any need for impairment of goodwill and trademarks in accordance with the accounting principles. The recovery value for cash-generating units has been established through calculation of value in use, which requires certain assumptions. The calculations are based on cash flow forecasts established by the management for the next five years. Cash flows after the five-year period are extrapolated with a growth rate that is assessed as reasonable on the basis of industry-specific companies.

### Capitalisation of development work

The Group carries out development work on IT support for healthcare, Cosmic, and estimates that 158.3 MSEK (164.1 MSEK) meets the requirements for capitalisation for the financial year. The capitalised amount is largely substantiated by contracted future income.

## Other

From time to time, the company engages in discussions with customers regarding contractual deliveries, which may result in commercial settlements. Management expects that outstanding trade receivables will be recovered in full.



## Parent company

Sanolium AB is a holding company that invests in fast-growing companies within the e-health industry. Sanolium AB has no employees.

### Income statement parent company

<b>MSEK</b>	<b>Q4 2025</b>	<b>Q4 2024</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Other revenue			4.5	4.1
Other external expenses	-1.2	-0.5	-7.7	-5.9
Financial net	-25.1	-27.9	-80.5	-84.6
Appropriations	3.2	4.9	3.2	4.9
<b>Net income</b>	<b>-23.1</b>	<b>-23.5</b>	<b>-80.5</b>	<b>-81.5</b>

### Balance sheet parent company

<b>MSEK</b>	<b>2025-12-31</b>	<b>2024-12-31</b>
<i>Fixed Assets</i>		
Financial assets	1,827.1	1,816.1
<b>Total Fixed Assets</b>	<b>1,827.1</b>	<b>1,816.1</b>
<i>Current Assets</i>		
Other receivables	4.4	4.2
Other receivables - group	24.2	28.2
Prepaid expenses and accrued income	3.0	3.7
Cash	328.9	384.6
<b>Total Current Assets</b>	<b>360.5</b>	<b>420.7</b>
<b>Total Assets</b>	<b>2,187.6</b>	<b>2,236.8</b>
<i>Equity</i>		
Share capital	1.7	1.7
Non-restricted equity	1,015.4	1,083.3
Net income for the year	-80.5	-81.5
<b>Total Equity</b>	<b>936.6</b>	<b>1,003.5</b>
<b>Bond loan</b>	<b>984.8</b>	<b>980.0</b>
<i>Other liabilities</i>		
Other liabilities	112.2	108.9
Other liabilities - group	151.4	141.6
Accrued expenses	2.6	2.8
<b>Total Other Liabilities</b>	<b>266.2</b>	<b>253.3</b>
<b>Total Equity and Liabilities</b>	<b>2,187.6</b>	<b>2,236.8</b>

## Changes in parent company equity

<b>MSEK</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Opening balance	1,003.5	1,084.9
Total comprehensive income for the period	-80.5	-81.4
<b>Total change excluding owner transactions</b>	<b>923.0</b>	<b>1,003.5</b>
Shareholder contributions	13.6	
<b>Equity at the end of the period</b>	<b>936.6</b>	<b>1,003.5</b>
Attributable to equity holders of the parent company	936.6	1,003.5
Non-controlling interest	N/A	N/A

## Parent company cash flow

<b>MSEK</b>	<b>Jan-Dec 2025</b>	<b>Jan-Dec 2024</b>
Income after financial items	-80.5	-86.4
Adjusted for non-cash items	7.2	11.6
Changes in working capital	17.6	-103.3
Cash flow from operating activities	-55.7	-178.1
Derivative aquisition		-4.0
Bond issue less financing fees		977.0
Repayment of bond loans		-800.0
Cashflow from financing activities		173.0
Changes in cash and cash equivalents	-55.7	-5.1
Opening cash and cash equivalents balance	384.6	389.7
<b>Cash and cash equivalents by end of the period</b>	<b>328.9</b>	<b>384.6</b>

**Adjusted EBIT**

Income before non recurring items, financial net and tax.

**Adjusted EBITDA**

Income before depreciation, non-recurring items, financial net and tax.

**Adjusted EBITDA margin**

Adjusted EBITDA as a percentage of revenue.

**Cash conversion**

Operating cash flow divided by adjusted EBITDA.

**EBIT**

Income before financial net and tax.

**Non-recurring items**

Items excluded from the normal operating items e.g restructuring costs, costs related to introduction of a new ERP system, M&A related costs and costs regarding refinancing or to set a financing structure (excluding interest on external debt).

**Operating cash flow**

Adjusted EBITDA minus capital expenditures, capitalized R&D and net working capital changes.

## ABOUT CAMBIO

### Long-term outlook

The global trend of a constantly growing and aging population is driving the need to invest in health- and social care, especially in technologies that drives patient security, scalability, and efficiencies to allow for a redistribution of funds towards value accretive areas. In a world with limited resources these areas of care face increasing pressure to become more productive and efficient, resulting in a greater demand for digitization. A key pillar of the digital transformation is communication and in particular the way in which health- and social care institutions interact. Open systems with standardized data that enables an ecosystem approach and optimized utilization of data is key to the development of a future-proof way of working.

Today there is a sizeable gap between the available technologies and the technical solutions used by health- and social care organizations. Cambio's solutions address that technology gap, resulting in a strong and sustainable demand for our offerings.

### Products and technology

Cambio's vision is to create a healthier tomorrow by enabling tomorrow's healthcare today. We do this through delivering high quality, open and collaborative digital solutions.

Cambio offers a wide range of digital solutions supporting health and social care. Cambio COSMIC, is a healthcare information system used in university hospitals, primary care clinics and community care homes. Cambio COSMIC is built on a modern proprietary platform with a wide range of associated subsystems and modules supporting various healthcare disciplines. Cambio Viva is used in municipalities. It is an operating system used to coordinate the activities and processes of social services, health and care professionals. Viva's proprietary platform enables a digital working environment supporting work processes and organizational developments and changes. In addition to these two major product categories, Cambio offers other specialist services and solutions. Cambio is also preparing to deliver Managed Service offering in the future.

### Customers

20 out of 21 regions and around 145 municipalities in Sweden are customers to Cambio. The ambition is to increase the number of customers and to increase the depth and breadth of our product offering so that end users benefit from as much support as possible. In Finland, Denmark and the UK, Cambio offers a wide range of products, and our ambition is to reach more end users with relevant offerings over time.

20 of 21  
regions

## Sustainability

Cambio's business model is built on accelerating sustainability in organizations within health- and social care. Cambio's sustainability report is published on [www.cambiogroup.com](http://www.cambiogroup.com) under Investor Relations.

### Financial calendar

Interim report Q1 2026, Jan – March, 2026-05-29  
Interim report Q2 2026, April – June, 2026-08-31  
Interim report Q3 2026, July – Sep, 2026-11-30  
Year end report 2026, 2027-02-26



### Presentation of the interim report

Cambio's interim reports will be published at [cambiogroup.com](http://cambiogroup.com) at each of the dates stipulated above.



### Information

For further information, please contact:  
Johannes Fabó, CFO +46 730 599 368  
[johannes.fabo@cambio.se](mailto:johannes.fabo@cambio.se)



### Sanolium AB

Cambio Healthcare Systems AB  
Sveavägen 44  
113 34 Stockholm

+46 8 691 49 00  
[info@cambio.se](mailto:info@cambio.se)



This report has not been reviewed by the company's auditors.